Long awaited results from INTerpath-001, the first Phase 3 trial to demonstrate efficacy of a personalized mRNA therapy! Intismeran met key endpoints in melanoma $MRNA $MRK A pivotal advance in personalized medicine! #ESMO26 https://t.co/OU80OoG64L